Project Grant R01HL188100
Award Date 8/15/26
Completion Date 4/30/31
Dollars Obligated $760K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $531,794 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of microRNA-98-5p (mir98) in myocardial ischemia-reperfusion injury during late pregnancy. The research addresses the mechanism underlying increased myocardial infarct size in late-pregnancy rats compared to non-pregnant rats. Prior work from the recipient's laboratory demonstrated a...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $124,688 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode the gene regulatory network of mammalian cardiac maturation. The award funds a K99/R00 research project investigating the molecular mechanisms driving postnatal cardiac development. During the K99 phase, the recipient will characterize epigenomic changes in the mouse heart during...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.272968 million on September 9, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-dependent regulation of cardiac cyclic AMP, excitation-contraction coupling, and arrhythmia by phosphodiesterases. The research addresses autonomic dysregulation and aberrant intracellular signaling in both heart failure with reduced ejection fraction and heart failure with...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.564 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of long noncoding RNAs and micropeptides in inflammation, lipid metabolism, and atherosclerosis. The project spans two research aims. Aim 1 examines a macrophage micropeptide named BRIK, testing its role in integrating metabolic and immune signaling and its contribution to...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded the University of California, Los Angeles $3,134,805 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on alternative polyadenylation in cardiovascular disease. The recipient will integrate computational techniques with molecular, cellular, and animal model studies to elucidate how alternative polyadenylation (APA) contributes to cardiovascular...
- The National Heart, Lung, and Blood Institute awarded The University of Chicago $817,976 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop single molecule footprinting methods for studying gene regulation in cardiac differentiation and disease. The recipient will combine methyltransferase-based chromatin measurement with native long-read sequencing to assess chromatin accessibility, nucleosome positioning, transcription factor binding, and DNA...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, operating as Lawrence Berkeley National Laboratory, $2,057,231 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to map and decode the enhancer landscape of human heart development. The award funds a research project that creates a single-cell enhancer atlas of the developing human heart by integrating genome-wide single-cell multiome data from critical...
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $1,585,727 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epigenomic mechanisms of cardiac fibrosis and heart failure. The project tests the hypothesis that the transcriptional regulator Meox1 functions as a key driver of fibroblast activation, myocardial fibrosis, and heart failure pathogenesis, leveraging novel genetic mouse models, cell lines, and...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $543,957 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how evolving extracellular matrices drive maturation of human pluripotent stem cell-derived cardiomyocytes. The research tests the hypothesis that cardiomyocyte maturation is enhanced through signaling of an evolving extracellular matrix deposited by cardiac fibroblasts in response to dynamic...